Sector News

Nestle pushes further into health science with Seres investment

January 7, 2015
Life sciences
(Reuters) – Nestle Health Science has invested $65 million in U.S.-based drugmaker Seres Health Inc, the latest move by its parent company Nestle to diversify away from packaged food.
 
Nestle has been expanding its reach into the fast-growing market for healthcare products that have higher margins than the instant soups, breakfast cereals and coffee the world’s biggest food group is generally known for.
 
The investment will help fund the next stage of development of Seres’ lead product candidate against clostridium difficile infection (CDI) – a bacterial infection of the digestive system – into late-stage clinical trials and help advance its other treatments against infectious, metabolic and inflammatory diseases, Nestle said on Tuesday.
 
Nestle Health Science also said on Tuesday it had entered into a strategic partnership with Seres’ venture capital backer, Flagship Ventures, to support start-ups working on nutritional health and therapy in view of potential further minority direct investments, licensing deals, joint ventures or acquisitions.
 
Nestle set up Nestle Health Science in 2011 to develop new therapeutic approaches for gastrointestinal, metabolic and brain disorders and other health conditions.
 
(Reporting by Silke Koltrowitz; editing by Susan Thomas)

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach